Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Multiple myeloma is a type of cancer where plasma ... of anemia or kidney failure wasn’t associated with a worsened survival rate. Researchers concluded that the development of bone disease ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... involving whether tandem ASCT improves progression-free survival (PFS ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

It was once the standard of care for patients with relapsed or refractory multiple myeloma. Overall response rate (ORR): percentage of patients ... Progression-free survival (PFS): time patients live ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...